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SUMMARY
Background
The optimal oral anti-viral agent to use in patients with decompensated
HBV cirrhosis remains unclear.
Aim
We performed a meta-analysis of the oral nucleos(t)ide analogues in
patients with decompensated HBV cirrhosis.
Methods
One year efﬁcacy and safety outcomes in 22 studies published in English
between 1995 and 2010 were analysed.
Results
Substantial heterogeneity was noted in the inclusion/exclusion criteria, con-
trols, and sensitivity of the HBV DNA assay used. Pooled 1-year data
showed beneﬁt favouring lamivudine (LAM) vs. untreated controls for
Child-Turcotte-Pugh (CTP) score improvement by  2 (OR: 117 (15 921),
P  0.0001) and transplant-free survival (OR: 3.2 (1.2, 9), P = 0.022).
Adefovir (ADV) led to undetectable HBV DNA at 1-year in 41% compared
to 83% with LAM and 80% with entecavir (ETV). Overall, 1-year trans-
plant-free survival rates varied from 78% with LAM to 95% and 94% with
Tenofovir (TDF) and Telbivudine (TBV), respectively. The 1-year incidence
of drug resistant HBV was 0% with ADV, ETV and TDF and 11% with
LAM although TBV was associated with a 29% incidence at 2 years. Drug-
related adverse events were infrequently reported.
Conclusions
All the oral anti-viral agents were associated with improved virological, bio-
chemical and clinical parameters at 1-year. However, the efﬁcacy of lamivu-
dine and telbivudine is limited by drug resistance, and adefovir is limited by
its potency and slower onset of action. Additional studies of tenofovir and
entecavir are needed to determine the optimal agent(s) for treatment naïve
patients and in those with drug-resistant decompensated HBV cirrhosis.
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INTRODUCTION
An estimated 15–40% of untreated patients with chronic
hepatitis B virus (HBV) infection may develop cirrhosis,
liver failure and/or hepatocellular carcinoma (HCC).1, 2
The goal of anti-viral therapy in these patients is to pre-
vent the development of cirrhosis and its associated
complications in an effort to improve patient survival
and quality of life.3 However, patients with decompensat-
ed HBV cirrhosis at initial presentation have a poor
short-term prognosis with an estimated 5-year survival
of only 14%.4 Although liver transplantation (LT) is an
effective treatment option for decompensated HBV cir-
rhosis, the ongoing shortage of donor organs and limited
availability of this resource worldwide precludes the
majority of HBV patients in endemic areas from under-
going transplantation.5 Therefore, the development of
anti-viral agents that can safely and effectively suppress
HBV replication and lead to improvement or stabilisa-
tion in liver function represents an important unmet
medical need.
Natural history studies have demonstrated that sus-
tained, active HBV replication with high serum HBV
DNA levels is associated with a poorer prognosis com-
pared to HBV patients with low or undetectable HBV
DNA.5, 6 In addition, a randomised controlled trial
(RCT) in Asian HBV patients with advanced but com-
pensated ﬁbrosis and high HBV DNA levels demon-
strated that lamivudine (LAM)-treated patients were less
likely to experience liver related morbidity and mortality
compared to untreated controls.7, 8 Seven drugs are cur-
rently approved for the management of chronic HBV
infection: standard interferon or IFN (Early 1990’s),
LAM (1997), adefovir or ADV (2002), entecavir or ETV
(2005), peginterferon-a2a or PEGIFN (2005), telbivudine
or TBV (2006) and Tenofovir or TDF (2008).6 Interfer-
ons enhance host immunity against HBV-infected
hepatocytes but have a number of dose-dependent side
effects including neuropsychiatric toxicity and myelotox-
icity which preclude their safe use in patients with
advanced HBV.6 For example, interferon was not only
poorly tolerated in patients with decompensated HBV
cirrhosis but also associated with disease ﬂares and wors-
ening liver disease status.9 In contrast, oral anti-viral
agents have a generally favourable side effect proﬁle and
are well tolerated in patients with compensated as well
as decompensated HBV.7 In addition, these agents can
directly and rapidly inhibit HBV replication and lead to
improvement in hepatic necroinﬂammation, serum ala-
nine aminotransfersase (ALT) levels and global liver
function even in patients with advanced disease.7 How-
ever, many of the studies in patients with decompensated
HBV have been small pilot protocols with variable inclu-
sion criteria and without an active contemporary control
arm. In addition, many of these studies were not
designed to establish the safety and efﬁcacy of these
drugs in this challenging patient population but rather to
provide early access to the medications. The aim of this
systematic review is to evaluate the efﬁcacy and safety of
the ﬁve available oral anti-viral agents in patients with
decompensated HBV cirrhosis including the nucleoside
analogues (lamivudine, entecavir and telbivudine) and
nucleotide analogues (adefovir and tenofovir). Based
upon the pooled 1-year safety and efﬁcacy data, we
sought to identify the preferred agent(s) for use in
patients with decompensated HBV cirrhosis.
MATERIALS AND METHODS
Study selection
Search strategy. Electronic databases (Medline, Cochra-
ne reviews, and EMBASE, ISI Web of science) from
1995 through 2010 were searched for publications
including abstracts in English language. The initial
search terms were hepatitis B, cirrhosis and treatment.
The search was later expanded using the MeSH terms
lamivudine, adefovir, entecavir, tenofovir and telbivudine.
Boolean logic was used to combine the words. In addi-
tion, manual search was made for cross references from
manuscripts.
Criteria for study selection. Both authors reviewed the
literature for study selection including references from
the included studies. All the studies that were included
were carefully reviewed by both authors to insure that
the studies met the pre deﬁned selection criteria of (i)
Patient population – adult patients with decompensated
HBV cirrhosis (treatment naïve as well as treatment
experienced) deﬁned as CTP score of 7 or more; (ii)
Treatment regimen– oral nucleos(t)ide analogues either
alone or in combination; (iii) Study design – any design
including retrospective or open-label prospective studies
with or without a control group. Efﬁcacy and safety data
of individual drugs in comparative studies were analysed
separately. Studies with a total sample size of <20 were
excluded as were studies of patients with a previous or
newly diagnosed HCC, children and liver transplant
recipients.
Assessment of study quality. A quality score for each
study was determined using several binomial parameters
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(Table S1).10, 11 Parameters were chosen based on their
relevance to the analysis of observational studies. Each
parameter was given a numerical score of 0 or 1 with an
overall quality score ranging from 0 to 10. Studies with a
quality score of <5 were rated as poor while those  5
were rated as high quality studies.
Outcome measures
Efﬁcacy and safety outcomes at 1 year after starting
treatment were evaluated. Efﬁcacy measures were cate-
gorised as: (i) Virological – proportion of patients with
undetectable HBV DNA, HBeAg loss and HBeAg sero-
conversion (i.e. HBeAg loss and anti-HBe positivity); (ii)
Biochemical – proportion of patients with normalisation
of elevated baseline serum alanine aminotransferase
(ALT) levels and; (iii) Clinical – proportion of patients
with improvement of CTP score by  2 points, LT-free
survival deﬁned as proportion of patients surviving with-
out LT, overall survival deﬁned as proportion of patients
surviving with or without LT, proportion of patients
developing HCC, and proportion of patients being
removed from the LT waiting list due to clinical
improvement. Safety for each drug was evaluated with
the following outcomes at 1 year (i) proportion of
patients with drug-related serious adverse events; (ii)
proportion of patients with renal insufﬁciency deﬁned as
an increase in serum creatinine by 0.5 mg/dL from base-
line; and (iii) proportion of patients with conﬁrmed drug
resistant HBV determined using direct sequencing or
line probe assay.
Data collection and analysis
Data were extracted for (i) Study characteristics (author
and year of publication, country of origin, study design,
sample size, study quality); (ii) Patient demographics
(age, gender, ethnicity, per cent HBeAg positive); (iii)
Inclusion and exclusion criteria; (iv) Treatment details
(anti-viral agent used, dose of drug, duration of treat-
ment, lower limit of detection (llod) for HBV DNA assay
used and duration of follow-up); and (v) Study outcomes
at 1 year after starting the treatment. Data were
extracted from each study by AKS and conﬁrmed for
accuracy by RJF who independently read through each
study. If the outcomes data were not clear from the
manuscript, the corresponding authors were contacted
for further information. Individual data for each out-
come were entered into the Comprehensive meta-analy-
sis software (Biostat, Engelwood, NJ, USA). Pooled
effects with 95% conﬁdence interval (CI) are reported
for the uncontrolled data while odds ratios (OR) with
95% CI are reported for studies with a control group of
untreated patients.Heterogeneity of the pooled data was
reported using the Chi-squared or Q statistic using a
random effects model. Publication bias was assessed
looking at the funnel plots and analysed using the
Egger’s test. Results were considered signiﬁcant for
P-value of <0.05.
RESULTS
Characteristics of the included studies
A total of 22 studies of nucleos(t)ide analogues fulﬁlled
the criteria for this systematic review (Figure 1 and
Table 1). Of the 14 studies evaluating LAM (two
abstracts), eight were open-label studies, four compared
LAM to untreated or historical controls, and two com-
pared LAM to either ETV or TBV.12–25 Five studies eval-
uated ADV(one abstract), of which two were open-label
and three had a comparator group (LAM + ADV in two
and ETV alone in one).26–30 Five studies evaluated ETV
3901 Total articles found
2233 Excluded
1627 Excluded
14 Excluded
4 Excluded
-Sample size < 20 (N = 4)
-Reviews (n = 787)
-Case reports (n = 57)
-Treatment of CHB without
cirrhosis (n = 783)
- Interferon treatment  (N = 10)
- Duplicate studies  (N = 2)
26 studies of oral agents in decompensated HBV cirrhosis
22 studies included for analysis
41 articles of treating patients with advanced HBV cirrhosis
-- Compensated cirrhosis
(N = 3)
-- HIV or HCV coinfection
1668 articles related to HBV
Figure 1 | Attrition diagram for study selection. Of the
3901 studies initially identiﬁed from our electronic
search, 22 met the inclusion criteria and were included
in this systematic review.
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(three abstracts), of which only one study was open-label
and the remaining four had a comparator group (LAM
+ ADV, LAM, ADV, TDF in one study each).24, 30–33
Tenofovir and TBV were evaluated in one randomised
controlled study each and compared to ETV and LAM,
respectively.25, 31 Of note, one RCT comparing LAM to
placebo and another comparing LAM to ADV were
excluded from this review since these studies included
compensated patients with CTP scores of  6.7, 34
Baseline characteristics of the patients enrolled in
the studies demonstrated a highly variable sample size
that ranged from 20 to 269 treated patients (Table 1).
A total of 15 (68%) studies were conducted in North
America or Europe whereas 7 (32%) included patients
only from Asia. Two of the seven Asian studies did
not have access to LT. There was great variability
among the studies regarding inclusion criteria (e.g.
mean CTP score at entry, percent HBeAg positive),
exclusion criteria (co-infection with HCV and/or HIV,
HCC, acute liver failure), and the llod of the HBV
DNA assay used (Table 1). Furthermore, the selection
of controls was variable among the controlled studies.
Nonetheless, the majority of the studies15 were of
good quality with a total quality score of  5 (see
Table S1).
Efﬁcacy analysis
Virological response. Analysis of the pooled 1-year
open-label data showed beneﬁcial effects for LAM, ADV
and ETV regarding the proportion of patients with
undetectable HBV DNA, HBeAg loss and HBeAg sero-
conversion (Table 2). Lamivudine and ETV were associ-
ated with similar rates of undetectable HBV DNA at
1 year of 83% and 80%, respectively. However, ADV was
less potent with only 41% of the ADV-treated patients
having undetectable HBV DNA at 1 year and the 95%
CI for the pooled ADV studies did not overlap with
those of the pooled LAM nor ETV studies (Table 2).
However, the rates of HBeAg loss and HBeAg serocon-
version were similar with these three agents (Table 2).
Compared to untreated control patients, LAM was also
signiﬁcantly better in achieving undetectable HBV DNA
at 1 year of follow-up (Table 3 and Figure 2). However,
rates of HBeAg loss with LAM were not signiﬁcantly
higher compared to untreated controls (Table 3).
In one prospective RCT, ETV achieved higher rates of
undetectable HBV DNA at 1 year compared to LAM
(100% vs. 73%; P = 0.02) using a highly sensitive HBV
DNA assay.24 Entecavir was also superior in achieving
undetectable HBV DNA at 1 year compared to ADV in
another prospective RCT (57% vs. 20%, P = 0.0001).30
Although ETV (n = 22) and TDF (n = 45) were similar
in achieving undetectable HBV DNA at 1 year (73% vs.
71%; P = 0.89) in one RCT, TDF led to more frequent
HBeAg seroconversion compared to ETV (21% vs. 0%,
P = 0.023) but the number of HBeAg + treated patients
was very limited.31 The frequency of undetectable HBV
DNA at 1 year was similar with TBV compared to LAM
(40% vs. 36%, P = 0.12).25
Clinical response. The use of LAM, ADV and ETV was
also associated with a decrease in CTP scores of  2
points and normalisation of serum ALT (Table 2).
Transplant-free survival varied between 78% and 87% at
1 year with the various agents (Table 2). Other beneﬁcial
effects with the oral nucleo(t)side agents included
removal from the LT waiting list in 6% of patients
receiving ADV, 21% receiving LAM and 11% treated
with ETV.31 Development of HCC at 1 year was
reported in 3%, 7% and 6% of patients receiving LAM,
ADV and ETV, respectively, (Table 2). Comparison of
the pooled data of all ﬁve drugs together showed no sig-
niﬁcant differences from the pooling of the individual
agents with overlapping 95% CI (Table 2).
Similar beneﬁcial effects were seen with LAM treat-
ment in the controlled studies (Table 3). The odds of a
decrease in CTP by  2 points was 117 times higher
with LAM as compared to untreated patients (Table 3)
(P < 0.0001). These beneﬁcial effects translated into
improved transplant-free survival at 1 year for patients
treated with LAM as compared to untreated patients
(Figure 3). However, LAM was not effective in reducing
the incidence of HCC at 1 year compared to untreated
controls (Table 3).18
A single study of 195 patients comparing LAM
(n = 97) and TBV (n = 98) showed similar efﬁcacy for
mean CTP improvement (0.6 ± 0.3 vs. 0.4 ± 0.3,
P = 0.22) and serum ALT normalisation (50% vs. 58%,
P = 0.22) at 2 years whereas data were similar for 1-year
survival (88% vs. 94%, P = 0.11).25 In another study,
ETV (n = 100) and ADV (n = 91) were similar in
regard to the proportion of patients with stable or
decreased CTP scores (61% vs. 67%, P = 0.08). However,
ETV was superior to ADV for serum ALT normalisation
at 1 year (63% vs. 46%, P = 0.045).30 Finally, in an
ongoing study of 112 patients entered into a RCT of
three agents, ETV (n = 22) and TDF (n = 45) were sim-
ilar in their rate of serum ALT normalisation (55% vs.
57%; P = 0.80) and transplant-free survival at 1-year
(91% vs. 91%; P = 0.98).31
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Sensitivity analysis of the pooled studies
In Table 2, most of the viral and clinical efﬁcacy effects
were similar for LAM, ADV and ETV with the exception
of HBV DNA undetectability which was signiﬁcantly
lower with ADV. As a result, all of these data were then
pooled together with the TFV and TBV data to deter-
mine the overall pooled safety and efﬁcacy of the ﬁve
agents combined. To determine the importance of other
factors that differed amongst the studies, we conducted a
sensitivity analysis based upon the geographical location
of the studies, the availability of LT and the study quality
score. Geographical location could inﬂuence study results
Table 3 | Pooled effect of four lamivudine studies with an untreated control group in decompensated HBV cirrhosis
Lamivudine No treatment Effect size Heterogeneity
Egger’s
P
Studies
(N)
Sample
size Events
Sample
size Events OR (95% CI) P Q statistics P
↓ CTP  2 pts 2 53 27 53 0 117 (915–921) <0.0001 0.22 0.64 NA
Normal ALT 2 51 38 60 0 173 (22–1376) <0.0001 0.04 0.84 NA
Undetectable
DNA
4 149 115 193 29 117 (2–6574) 0.02 32 <0.0001 0.007
HBeAg loss 3 82 25 156 10 14 (0.3–563) 0.16 14.9 0.001 0.20
HBeAg
seroconversion
1 16 1 23 0 4.6 (0.2–12) 0.36 NA NA NA
Off OLT list 2 185 14 170 7 2 (1–5) 0.22 0.55 0.46 NA
LT 2 185 97 170 101 0.38 (0.1–3) 0.34 8.29 0.004 NA
HCC 1 30 2 30 2 1 (0.1–8) 0.17 0.60 0.44 NA
OLT free survival 4 245 155 216 87 5 (1.5–15) 0.022 8.59 0.035 0.31
Overall survival 4 245 214 216 87 14 (2–119) 0.017 35 <0.0001 0.82
Drug resistance 4 223 28 205 0 16 (4–72) <0.0001 0.71 0.87 0.02
CTP, child Turcotte Pugh; HCC, hepatocellular carcinoma; LT, liver transplantation; OR, odds ratio.
Study
Yao (12)
Perrillo (13)
Fontana et al. (14)
Manolakopoulos (17)
subgroupor
Lamivudine No treatment Odds ratio
0.001 0.1 10 10001
M-H, Random, 95% CIEvents Events TotalTotal
Total (95% CI)
Test for overall effect: Z = 2.20 (P = 0.03)
119.86 [1.68, 8560.29]
23 23
23
7157
23
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17
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22
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1000
0
0
Figure 2 | Pooled data from four controlled studies of lamivudine in achieving undetectable HBV DNA at 1 year in
decompensated HBV cirrhosis patients. At 1 year, 83% of the 139 lamivudine treated patients were negative for HBV
DNA as compared to 15% of the 193 untreated controls with an odds ratio of 120 (95% CI: 1.7–8560, P = 0.03).
Study
Yao (12)
Perrillo (13)
Fontana et al. (14)
Manolakopoulos (17)
subgroupor
Lamivudine No treatment
Events Events TotalTotal
Total (95% CI)
Test for overall effect: Z = 2.60 (P = 0.009)
23 23
24
91
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17
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55 100
162
0
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Figure 3 | Pooled data from 4 controlled studies of lamivudine on 1-year transplantation free survival in decompensated
HBV cirrhosis patients. At 1 year, 63% of the 249 lamivudine treated patients were alive without transplantation
compared to only 40% of the 216 untreated controls with an odds ratio of 4.7 (95% CI: 1.5–15, P = 0.009).
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since HBV genotypes, routes of HBV transmission and
the natural history of chronic HBV differ in eastern vs.
western countries. Similarly, subjects managed at a liver
transplant centre may have a better 1-year survival com-
pared to those without access to LT. Lastly, the impact
of treatment efﬁcacy may be better discerned in studies
with a high vs. low quality score. Per supplementary
Table S2, the geographical location of the studies did not
impact any of the pooled efﬁcacy parameters measured.
However, patients treated at liver transplant centres had
a lower transplant-free survival presumably due to their
ability to undergo transplantation and these patients also
had a signiﬁcantly higher rates of HBeAg seroconversion.
Furthermore, the patients enrolled in higher quality stud-
ies (i.e. quality score  6) that were more often prospec-
tive, controlled trials demonstrated a signiﬁcantly lower
overall survival rate compared to the patients enrolled in
the lower quality studies which may be due to prospec-
tive tracking of patient outcomes. Lastly, the llod of the
HBV DNA assay used in the LAM treatment studies did
not lead to any signiﬁcant differences in any of the efﬁ-
cacy outcomes reported (Table S3).
Safety analysis
Adverse events and renal insufﬁciency. None of the
studies of lamivudine reported any serious adverse events
(SAE) associated with this agent. Adefovir was associated
with an SAE in 4% of treated patients with a low serum
phosphate reported in 4 of 226 (2%) patients in one
study.28 Entecavir was associated with an SAE in 6% of
treated patients in a pooled analysis of two studies.31 In
addition, a comparison of ADV and ETV in one pro-
spective study and of TDF and ETV in another prospec-
tive study showed similar rates of SAE’s (4% vs. 0%,
P = 0.89) and (7% vs. 9%, P = 0.72), respectively.30, 31
Renal insufﬁciency deﬁned as an increase of serum
creatinine by  0.5 mg/dL over baseline occurred in 9%
(5–17%) of patients treated with ADV and 10% (6–17%)
of patients treated with ETV (Table 2). In contrast, none
of the studies using LAM reported any instances of renal
insufﬁciency. In the prospective RCT of TBV and LAM,
there was a greater improvement in the calculated esti-
mated glomerular ﬁltration rate (GFR) from baseline
amongst patients treated with TBV as compared to LAM
(3.3 ± 3.3 mL vs. 4.3 ± 3.1 mL, P = 0.02).25 In another
study, the incidence of renal insufﬁciency at 1-year was
similar with ETV and TDF (5% vs. 9%, P = 0.53).31
Drug resistance. The pooled rate of drug resistant HBV
at 1-year with LAM of 11% (8–14%) was signiﬁcantly
higher than that seen with ADV (0%) and ETV (0%)
(Table 2) However, two patients with pre-existing LAM-
resistant HBV developed an additional point mutation
that prompted a switch to TDF with continued suppres-
sion of HBV replication in one ETV study.31 Finally, a
trend towards a higher rate of drug resistance was seen
with LAM compared to TBV after 2 years of treatment
(39% vs. 29%; P = 0.12).25
DISCUSSION
A recent systematic review of anti-viral therapy in treat-
ment naïve chronic HBV patients demonstrated that
ETV and TDF are the preferred ﬁrst line oral anti-viral
agents due to their potency and low rate of inducing
drug-resistant mutations during prolonged therapy.
However, that systematic review only included RCTs of
the available agents in patients with compensated
chronic HBV.36 Therefore, the aim of the current sys-
tematic review was to assess the efﬁcacy and safety of
the various oral anti-viral agents in patients with decom-
pensated HBV cirrhosis. The size and design of these
studies was quite heterogeneous (Table 4). Overall, the
largest amount of data involved lamivudine monotherapy
in decompensated HBV cirrhosis presumably due to the
fact that this agent has been available for over 15 years
in many countries. However, many of the early lamivu-
dine studies did not have a contemporary control group
and used fairly insensitive HBV DNA assays with a llod
of 105 copies/mL (i.e. 43% of LAM studies) which may
lead to an overestimate of its anti-viral efﬁcacy and
underestimate the rate of drug-resistant HBV. Nonethe-
less, signiﬁcant objective improvements in liver disease
severity were consistently noted with LAM compared to
untreated controls. For example, LAM use in 245
patients was associated with an approximately threefold
higher rate of 1-year transplant-free survival compared
to 230 untreated controls (P = 0.022) (Table 3). How-
ever, resistance to lamivudine which occurred in 11% of
these patients at 1 year has emerged as a major limita-
tion particularly in patients with advanced disease who
do not tolerate biochemical ﬂares with emergence of
drug-resistant HBV.5 In addition, the RCT of LAM vs.
placebo in compensated HBV cirrhosis patients demon-
strated a higher rate of clinical outcomes in those who
developed drug resistance during follow-up compared to
those without resistance (11% vs. 5% at 32 months,
P = 0.031) and a higher mortality rate in those with
decompensation and drug-resistant HBV during post-
treatment follow-up vs. the placebo-treated patients (35%
vs 10% P = 0.043).7, 8
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The majority of patients treated with adefovir had
pre-existing LAM resistant HBV and many were treated
with LAM and adefovir combination therapy (Table 1).
Pooled data on the efﬁcacy of ADV were comparable to
LAM for serum ALT normalisation, improvement of
CTP score and transplant-free survival. However, ADV
was less potent with a slower onset of action compared
to LAM with only 41% of patients having undetectable
HBV DNA at 1 year compared to 83% with LAM
(Table 2). Although, drug-resistant HBV was not
reported in the 303 ADV-treated patients in this pooled
analysis, the cumulative rate of ADV resistance is 29% at
5 years among compensated chronic HBV patients
receiving ADV monotherapy.37 These observations com-
bined with the known dose-dependent nephrotoxicity of
ADV make it a less attractive option for prolonged use
in patients with decompensated HBV cirrhosis who fre-
quently have unstable renal function.
The pooled data of ETV monotherapy in 243 patients
with decompensated HBV cirrhosis showed anti-viral
efﬁcacy and suppression of HBV DNA to undetectable
levels that was similar to that observed with LAM (80%
vs. 83%) (Table 2). Of note, the incidence of undetect-
able HBV DNA was signiﬁcantly higher with ETV com-
pared to LAM in one RCT of 48 patients using a highly
sensitive assay with a llod of 300 cp/mL (100% vs. 73%,
P = 0.02).24 Furthermore, none of the ETV-treated
patients demonstrated evidence of entecavir resistant
HBV at 1 year despite the presence of lamivudine resis-
tant HBV in some of these patients. However, it should
be noted that prolonged use of ETV at a dose of 1 mg
per day in compensated HBV patients with lamivudine-
resistant HBV is associated with a cumulative rate of
entecavir-resistant HBV in up to 50% of patients treated
for 5 years.38
Data on the use of TDF and TBV in decompensated
HBV cirrhosis are restricted to one study for each drug.
Tenofovir was as effective and potent as ETV with a
similar side effect proﬁle and no evidence of drug-resis-
tant HBV at 1 year in a RCT of 112 total patients. In
addition, 21% of the TDF treated patients were able to
achieve HBeAg seroconversion and 4% lost HBsAg.
Telbivudine was as effective as LAM with a similar side
effect proﬁle but TBV was also associated with a 29%
rate of drug resistance at 2 years.25 In addition, recent
studies have demonstrated an increasing frequency of
serum CPK elevations with prolonged telbivudine use.39
Therefore, it would appear that TBV may be a second
line agent for patients with decompensated HBV
cirrhosis due to safety concerns.
Going forwards, a larger number of patients with
drug-resistant HBV will likely be encountered in clinical
practice who may present with decompensation in the
midst of a biochemical ﬂare. For example, 44 of the 122
(36%) liver transplant candidates enrolled in the HBV
OLT study that received anti-viral therapy developed
drug resistance during follow-up.22 In a study of 53
patients with LAM-resistant HBV, TDF was superior to
ADV in suppressing HBV DNA to undetectable levels at
1 year (100% vs. 44%; P = 0.001).40 In addition, TDF
was also shown to suppress as many as 80% of compen-
sated patients with documented resistance to ADV and
or LAM to undetectable levels.41 Therefore, TDF may be
of particular value in patients with drug-resistant HBV
that present with decompensated cirrhosis. However,
there are some concerns regarding the long-term safety
of tenofovir in patients with malnutrition and low vita-
min D levels.42 Therefore, additional prospective studies
with careful assessment of renal function and metabolic
bone disease are needed with TDF treatment in decom-
pensated HBV patients.
Drug safety is an important consideration when treat-
ing any disease and particularly so in patients with
decompensated cirrhosis who have impaired drug metab-
olism, protein binding, and renal function. In our sys-
tematic review, LAM had the fewest number of SAE’s
reported which may, in part, relate to the retrospective
nature of many of the LAM studies. Renal insufﬁciency
with associated renal tubular dysfunction was reported
in 6% of ADV-treated patients on the LT waiting list,
3% of treated patients with compensated cirrhosis and
21% of LT recipients.28, 37, 43, 44 In our pooled analysis,
the incidence of renal insufﬁciency with ADV was 9%
which is likely an underestimate due to the lack of con-
sistent monitoring in these studies.28, 30
Renal insufﬁciency was also reported in 10% of
patients treated with ETV in our systematic review
(Table 2). This is in contrast, to the experience with pro-
longed ETV therapy in compensated HBV cirrhosis
wherein no cases of renal insufﬁciency were noted.6, 45
The high rates of renal insufﬁciency observed in two of
these studies is likely due to inclusion of patients with
low baseline GFR.30, 31 Tenofovir was also associated with
renal insufﬁciency in 4 (9%) of the 45 patients treated in
one study and the need for dose reductions in three addi-
tional patients.31 In contrast, none of the patients treated
with TBV developed renal insufﬁciency and in fact the
mean GFR actually increased by 3.3 mL/min at 1 year.25
Another concern with the prolonged use of nucleos(t)
ide analogues is the potential for mitochondrial toxicity
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which may present with myopathy, neuropathy, rhabd-
omyolysis and lactic acidosis.44–46 In the current analysis,
lactic acidosis and mitochondrial toxicity were reported
in only one of the 100 ETV-treated patients and it sub-
sided despite continuing ETV.30 Serious adverse effects
with ETV also occurred in only 6% of treated patients
consistent with the favourable safety proﬁle of ETV in
patients with compensated HBV cirrhosis.47 However, an
awareness of this adverse event and how it might present
is critical when using these agents in patients with
advanced chronic HBV.48
Several limitations regarding our systematic review
require comment. Firstly, the inclusion criteria and study
design varied greatly amongst the studies examined.
However, all the study patients had decompensated liver
disease and we were able to assess virological, biochemi-
cal and clinical parameters in the majority of studies
(Table 1). Nonetheless, the heterogeneity in patient popu-
lations leads to a lower level of conﬁdence in the accuracy
of the pooled estimates. Secondly, the more recent studies
of TDF, ETV and TBV all tended to use more sensitive
assays for HBV DNA compared to the early LAM and
ADV studies which limits our ability to directly compare
the extent of viral suppression. Nonetheless, the overall
rate of HBeAg seroconversion and ALT normalisation
was fairly similar across the agents. In addition, there was
only a single study of TDF and TBV which limits our
ability to make recommendations regarding these agents.
However, the use of randomised, controlled study designs
with prospective assessment of clinical, virological and
safety parameters with the newer agents provides higher
quality data as reﬂected in the data quality scores (Table
S1). Lastly, we were unable to complete a cost-effective-
ness analysis comparing the available drugs due to the
lack of quality of life data and associated costs of clinical
care in most studies.
In summary, our systematic review indicates that all
of the available oral agents can lead to improved virolog-
ical, biochemical and clinical parameters amongst
patients with decompensated HBV cirrhosis at 1 year of
follow-up (Table 4). Furthermore, use of these agents in
decompensated HBV patients is generally safe and well
tolerated at 1 year but the increasing incidence of neph-
rotoxicity with prolonged ADV therapy and its slower
onset of action make it a less attractive option for this
patient population. In addition, the increasing rates of
drug-resistant HBV with prolonged use of LAM, ADV
and TBV monotherapy make these three agents less
attractive for decompensated HBV patients. Therefore,
although ETV and TDF had similar 1-year efﬁcacy to
LAM and TBV in our study, the lower rate of drug resis-
tance associated with these drugs during prolonged use
would make them more attractive as initial agents for
decompensated HBV patients who require life-long treat-
ment.6 Our systematic review also highlights the need
for additional prospective studies on the long-term safety
and efﬁcacy of TDF and ETV in a large cohort of previ-
ously untreated decompensated patients that are pro-
spectively monitored for compliance, anti-viral drug
resistance and safety parameters. In addition, further
studies of the risks and beneﬁts of these two agents in
patients with drug-resistant HBV are needed to assist cli-
nicians in the management of this expanding pool of
patients.
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